News, Trends, Challenges in Specialty Pharmacy: Rx Drug Manufacturers, Benefits Decision Makers Find Solutions in AscellaHealth Developments in Specialty Pharmacy Newsletter

News, Trends, Challenges in Specialty Pharmacy: Rx Drug Manufacturers, Benefits Decision Makers Find Solutions in AscellaHealth Developments in Specialty Pharmacy Newsletter




News, Trends, Challenges in Specialty Pharmacy: Rx Drug Manufacturers, Benefits Decision Makers Find Solutions in AscellaHealth Developments in Specialty Pharmacy Newsletter

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces its innovative newsletter, Developments in Specialty Pharmacy, featuring insights, perspectives and solutions for utilization of expensive specialty drugs and gene therapies that address complex diseases, as well as orphan and rare disorders and in-depth, exclusive interviews with industry partners, such as the Muscular Dystrophy Association (MDA) and Dr. A. Mark Fendrick, M.D., director, Value-Based Insurance Design Center.

“We’re pleased to present this timely and robust issue of our industry-focused newsletter, which is filled with valuable information that impacts employers, plan sponsors, payers, manufacturers, providers, advocacy groups, government regulators and industry consultants,” says Dea Belazi, president and CEO, AscellaHealth. “Our team has gathered targeted and relevant specialty pharmacy industry content to help readers address an evolving—often complicated—marketplace where expensive treatments are straining the healthcare budgets of employer and payer communities and challenging pharmaceutical and biotech manufacturers to answer the call for innovative solutions with improved outcomes and alternative financing of high-cost specialty drugs.”

Newsletter spotlights:

  • AscellaHealth recognized as an Inc. 5000, 2021 fastest growing company
  • MDA’s significant impact on research and development for gene therapies for neuromuscular diseases
  • Value-based and outcomes-driven approaches for specialty pharmacy spending
  • Ongoing debate over cuts to 340B drug payments to hospitals, Federally Qualified Health Centers
  • Multiple orphan products, generics and biosimilars inundating the market and strategies for ensuring appropriate drug utilization and care management
  • FDA’s controversial approval of Biogen’s high-cost Alzheimer’s drug—and need for specialty pharmacy management to contain costs
  • Industry consultants, AscellaHealth thought leadership, upcoming healthcare awareness events – and more

Belazi adds, “AscellaHealth proactively provides industry-specific education and information that empowers specialty pharmacy stakeholders to implement solutions that create accountability and predictability around these expensive treatments and therapies. With robust research and development underway, there will be growing pressures to introduce these specialty drugs and potential cures.”

About AscellaHealth LLC

AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.

Contacts

Media:
Nicole Dufour

CPR Communications

ndufour@cpronline.com
201.641.1911 x 54